Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Long-Term Investments: 2018-2022

Historic Long-Term Investments for Arcturus Therapeutics Holdings (ARCT) over the last 1 years, with Mar 2022 value amounting to $131,000.

  • Arcturus Therapeutics Holdings' Long-Term Investments fell 89.50% to $131,000 in Q1 2022 from the same period last year, while for Mar 2022 it was $131,000, marking a year-over-year decrease of 89.50%. This contributed to the annual value of $515,000 for FY2021, which is N/A change from last year.
  • Per Arcturus Therapeutics Holdings' latest filing, its Long-Term Investments stood at $131,000 for Q1 2022, which was down 74.56% from $515,000 recorded in Q4 2021.
  • Arcturus Therapeutics Holdings' 5-year Long-Term Investments high stood at $1.2 million for Q1 2021, and its period low was $100,000 during Q1 2020.
  • Moreover, its 3-year median value for Long-Term Investments was $592,500 (2021), whereas its average is $597,333.
  • As far as peak fluctuations go, Arcturus Therapeutics Holdings' Long-Term Investments spiked by 1,148.00% in 2021, and later plummeted by 89.50% in 2022.
  • Over the past 5 years, Arcturus Therapeutics Holdings' Long-Term Investments (Quarterly) stood at $288,000 in 2018, then declined by 8.68% to $263,000 in 2019, then reached $100,000 in 2020, then surged by 1,148.00% to $515,000 in 2021, then plummeted by 89.50% to $131,000 in 2022.
  • Its last three reported values are $131,000 in Q1 2022, $515,000 for Q4 2021, and $670,000 during Q3 2021.